Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
Johnson & Johnson: You Need To Look At This Chart (Rating Upgrade)
11:10am, Thursday, 10'th Oct 2024
JNJ's current dividend yield is around the highest level in at least 10 years. The market's concern over its current issues - which are all temporary in my view - is drastically overblown. The overrea
Johnson & Johnson (JNJ) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
10:20am, Thursday, 10'th Oct 2024
Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its k
TREMFYA ® is now U.S. FDA-approved for ulcerative colitis and under review for Crohn's disease TREMFYA® is the only IL-23 inhibitor to demonstrate superiority to ustekinumab in the overall populat
Submission supported by data from the Phase 3 CEPHEUS study for the treatment of patients with newly diagnosed multiple myeloma for whom transplant is not planned as initial therapy1
Buy 4 October Dividend Aristocrats & Watch 10
12:17pm, Wednesday, 09'th Oct 2024
"Dividend Aristocrats... in the S&P500 Index… have raised their annual payouts every year for at least 25 consecutive years." -- Kiplinger.com/Investing. 67 Aristocrats, screened as of October 7, 20
Johnson & Johnson (JNJ) Completes Acquisition of V-Wave Ltd for $600 Million
11:32am, Wednesday, 09'th Oct 2024
Johnson & Johnson (JNJ, Financial) has finalized the acquisition of V-Wave Ltd, a private medical device company. The pharmaceutical giant agreed to purchase V-Wave for an upfront payment of $600 mill
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
10:06am, Wednesday, 09'th Oct 2024
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Should Investors Consider High Yield Dividend Stocks?
08:50pm, Tuesday, 08'th Oct 2024
When selecting dividend-paying stocks, one of the first things that investors look at is, of course, the annual yield.
What To Expect When Johnson & Johnson Reports Q3 Earnings Next Week?
02:00pm, Tuesday, 08'th Oct 2024
Monday, Johnson & Johnson JNJ said it discontinued the Phase 3 SunRISe-2 trial of TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy for muscle-invasive urothelial carcinoma (M
Analysts Estimate Johnson & Johnson (JNJ) to Report a Decline in Earnings: What to Look Out for
11:08am, Tuesday, 08'th Oct 2024
Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Undervalued Dividend Kings: October 2024
09:00am, Tuesday, 08'th Oct 2024
Dividend Kings have a 50+ year track record of increasing dividends, showcasing resilience through economic challenges. I rank Dividend Kings by quality score and highlight undervalued stocks for pote
Johnson & Johnson (JNJ) Halts TAR-200 Bladder Cancer Trial, Future FDA Plans Remain
02:50am, Tuesday, 08'th Oct 2024
Johnson & Johnson (JNJ, Financial) has announced the termination of its phase 2 trial for the TAR-200 therapy aimed at treating patients with muscle-invasive bladder cancer (MIBC). The decision follow
J&J discontinues late-stage study for bladder cancer drug
04:40pm, Monday, 07'th Oct 2024
Johnson & Johnson said on Monday it has discontinued a late-stage study testing its experimental drug to treat a type of bladder cancer as the drug did not show superior benefits compared to chemoradi
Should JNJ Stock Be in Your Portfolio Ahead of Q3 Earnings?
04:01pm, Monday, 07'th Oct 2024
JNJ's Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. It remains to be seen if MedTech sales improved.
Johnson & Johnson Scraps Phase II Study on Antiviral for Dengue Virus
02:01pm, Monday, 07'th Oct 2024
As part of the strategic re-prioritization, JNJ terminates the phase II field study on mosnodenvir for the prevention of the dengue virus.
